Join to View Full Profile
1475 NW 12th AveFl 1Miami, FL 33136
Phone+1 305-243-2581
Fax+1 305-243-1293
Dr. Trent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
McGovern Medical School at UTHealthClass of 1995
Certifications & Licensure
FL State Medical License 2011 - 2026
TX State Medical License 1997 - 2013
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Medical Oncology
The National Board of Physicians and SurgeonsMedical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Start of enrollment: 2005 Sep 01
- Ph II Study of Perifosine Plus Gleevec for Patients With GIST Start of enrollment: 2006 Aug 01
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST Start of enrollment: 2003 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma.William D Tap, Gregory M Cote, Howard Burris, Lia Gore, Anthony Elias
Clinical Cancer Research. 2025-03-18 - Large scale multi-omic analysis identifies anatomic differences and immunogenic potential in subtypes of leiomyosarcoma.Galina Lagos, Roman Groisberg, Andrew Elliott, Don S Dizon, Andreas Seeber
Clinical Cancer Research. 2025-03-18 - Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?Amrit Paudel, Priya Chattopadhyay, Brandon Rose, Aleksandra Watson, Gina D'Amato
Cancers. 2025-03-05
Press Mentions
Sylvester Recruits Aman Chauhan, M.D., to Lead Neuroendocrine Tumor ProgramMarch 16th, 2023- Sylvester Stands Out at ASCO’s 2022 Annual Meeting in ChicagoJune 21st, 2022
- Precision Medicine Advances in Cancer Treatment Highlighted at Inaugural Sylvester ConferenceApril 12th, 2022
- Join now to see all
Grant Support
- Chaperonin (Sulfolobus Shibatae)National Center For Research Resources2006–2009
- Activity &Resistance Of Gleevec In GI Stromal TumorsNational Cancer Institute2004–2008
- Mechanism/Activity/Resistance/Gleevec/Gi Stromal Tumors (K23M)National Cancer Institute2005–2006
- Chaperonins As Self-Assembling Building Blocks For NanotechnologyNational Center For Research Resources2005
- Characterize Struct Of Molecular Chaperones Cytostructure Of Prokaryotic CellNational Center For Research Resources1998
- Chaperonin Filaments Archaeal CytostructureNational Center For Research Resources1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
